Nexalin Technology stands at the forefront of the mental health treatment revolution with its cutting-edge, non-invasive neurostimulation technology. By focusing on deep brain stimulation, Nexalin's devices, particularly the advanced Gen-3 HALO™ Clarity, offer a groundbreaking alternative to traditional pharmacological treatments. This technology has shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—conditions that affect millions but have limited effective treatments—positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach $537 billion by 2030.

Recent strategic developments, such as the introduction of the Virtual Clinic, allow patients to receive treatment from the comfort of their homes, thereby enhancing Nexalin’s market differentiation and patient accessibility. Combined with the robust expansion of the Company’s intellectual property portfolio and regulatory approvals in multiple countries, these developments broaden Nexalin’s market presence and are expected to drive sustained shareholder value improvement. Nexalin offers investors an opportunity to invest in a company that is not just prepared for the future but is actively shaping it, offering a profound chance to improve mental health outcomes on a global scale.

• Innovative technology with proven clinical results
  • Pioneering non-invasive, frequency-based deep brain stimulation devices targeting treatment-resistant mental health disorders including PTSD, insomnia, depression, and more
  • Demonstrated improvements in sleep quality and mental health parameters, substantiated by multiple peer-reviewed studies
  • Positive outcomes from studies conducted at University of California, San Diego showing effectiveness in reducing PTSD and post-concussive symptoms
• Strategically positioned to address massive market opportunity
  • Mental health market projected to reach $537 billion by 2030
  • Recent market entry into the Middle East, with plans to expand into additional international markets
  • Regulatory approvals in Oman and China
  • FDA approval process underway
  • Committed to maintaining operational efficiency while scaling up production and clinical deployment
• Strong intellectual property protections
  • Robust IP portfolio with several patents issued and pending, protecting core technologies through 2040
• Experienced leadership and advisory board
  • Led by CEO Mark White, a pioneer in digital medical markets with direct experience in neuro-stimulation technologies
  • Core executive team includes Dr. David Owens (CMO) and Marilyn Elson (CFO), who together bring decades of experience in medical technology, clinical operations, and financial management
  • Supported by an advisory board with deep expertise in investment banking, global strategy, and product development